CTOs on the Move

Innovatient Solutions

www.innovatient.com

 
Innovatient helps healthcare organizations deliver better care through an interactive patient experience and engagement technology platform. The highly customizable software provides an easy-to-use solution delivered via TV, tablet, or bedside monitor engaging patients during treatment and after they go home, fostering an environment of wellness and improved outcomes. Our integrated nurse rounding, communication, and patient education tools result in improved patient satisfaction scores (HCAHPS) transforming the patient experience creating long-term relationships with healthcare providers.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Vision Group Holdings

Serving markets in the US and Canada, Vision Group Holdings oversees and manages the leading LASIK and laser eye surgery providers in North America.

Healthy Pet

Healthy Pet is a Shelton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

University Hospitals Rainbow Babies and Childrens Hospital

University Hospitals, one of the nation`s leading health care systems, focuses on providing compassionate, quality medical care to patients at convenient locations throughout Northeast Ohio.

Drugs.com

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Visit us at www.drugs.com.